Business Description
Nymox Pharmaceutical Corp
NAICS : 325412
SIC : 2835
ISIN : BSP733981026
Description
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.91 | |||||
| Equity-to-Asset | -2.84 | |||||
| Debt-to-Equity | -0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -444.99 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 27.3 | |||||
| 3-Year EPS without NRI Growth Rate | 28.3 | |||||
| 3-Year FCF Growth Rate | 18.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.01 | |||||
| 9-Day RSI | 41.37 | |||||
| 14-Day RSI | 42.87 | |||||
| 6-1 Month Momentum % | -68.5 | |||||
| 12-1 Month Momentum % | -31.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.25 | |||||
| Quick Ratio | 0.25 | |||||
| Cash Ratio | 0.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.3 | |||||
| Shareholder Yield % | 0.13 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 36360 | |||||
| Net Margin % | 97440 | |||||
| FCF Margin % | 88240 | |||||
| ROA % | -387.84 | |||||
| ROIC % | -477.67 | |||||
| ROC (Joel Greenblatt) % | -1454.62 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -16.43 | |||||
| EV-to-EBITDA | -18.86 | |||||
| EV-to-Revenue | -5583 | |||||
| EV-to-FCF | -6.12 | |||||
| Earnings Yield (Greenblatt) % | -6.09 | |||||
| FCF Yield % | -15.77 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:NYMXF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nymox Pharmaceutical Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | -0.005 | ||
| EPS (TTM) ($) | -0.05 | ||
| Beta | -0.27 | ||
| Volatility % | 435.56 | ||
| 14-Day RSI | 42.87 | ||
| 14-Day ATR ($) | 0.040858 | ||
| 20-Day SMA ($) | 0.344472 | ||
| 12-1 Month Momentum % | -31.51 | ||
| 52-Week Range ($) | 0.12 - 1.275 | ||
| Shares Outstanding (Mil) | 93.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nymox Pharmaceutical Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nymox Pharmaceutical Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nymox Pharmaceutical Corp Frequently Asked Questions
What is Nymox Pharmaceutical Corp(NYMXF)'s stock price today?
The current price of NYMXF is $0.30. The 52 week high of NYMXF is $1.27 and 52 week low is $0.12.
When is next earnings date of Nymox Pharmaceutical Corp(NYMXF)?
The next earnings date of Nymox Pharmaceutical Corp(NYMXF) is 2024-05-10 Est..
Does Nymox Pharmaceutical Corp(NYMXF) pay dividends? If so, how much?
Nymox Pharmaceutical Corp(NYMXF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers